美国50岁及以上成人中在研成人剂型21价肺炎球菌结合疫苗的成本效果
研究采用马尔可夫模型评估在研成人剂型21价肺炎球菌结合疫苗(PCV21)在美国50岁及以上成人中的成本效果,比较不同接种策略与现行推荐疫苗或无接种。从社会视角看,50/65岁接种PCV21相比仅50岁接种,在黑人队列每获得一个质量调整生命年(QALY)需7410美元,非黑人队列为85696美元/QALY。PCV21相比现行疫苗可能具有成本效果。
要点
- PCV21在50/65岁接种较仅50岁接种,社会视角下黑人队列每QALY花费7410美元,非黑人队列85696美元。
- 医疗视角下,50岁接种PCV21相比不接种,黑人队列每QALY花费46213美元,非黑人队列86629美元。
- 考虑儿童接种间接效应后,50/65岁接种PCV21的社会视角成本仍低于每QALY 140000美元。
核心结论
- 从社会视角和医疗视角看,PCV21相比现行获批的成人肺炎球菌疫苗,在美国50岁及以上成人中可能具有成本效果。
研究设计与样本
- 采用马尔可夫模型评估PCV21终身成本效果,模型参数基于美国数据。
- 在假设的黑人和非黑人50岁及以上队列中分析,并考虑或不考虑儿童肺炎球菌疫苗接种的间接效应。
- 通过单因素和概率敏感性分析评估参数不确定性。
主要发现
- 社会视角下,50/65岁接种PCV21相比仅50岁接种,黑人队列每获得QALY需7410美元,非黑人队列需85696美元/QALY。
- 50/65岁接种PCV21具有最有利的公共卫生结局。
- 医疗视角下,50岁接种PCV21相比不接种,黑人队列每获得QALY需46213美元,非黑人队列需86629美元/QALY。
- 所有其他策略在两个队列和两种视角下均被支配。
- 考虑儿童接种间接效应时,50/65岁接种PCV21的社会视角成本在两个人群中仍低于每获得QALY 140000美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Indirect effects of childhood pneumococcal conjugate vaccines (PCV) have diminished the cost-effectiveness of current adult vaccine recommendations. An in-development adult-formulated 21-valent pneumococcal conjugate vaccine (PCV21) may play a critical role in reducing pneumococcal illness by targeting a larger number of serotypes responsible for adult pneumococcal infections. This study assesses the cost-effectiveness of PCV21 in US adults aged 50 years or older compared with currently recommended pneumococcal vaccines, from both the societal and healthcare perspectives. A Markov model evaluated the lifetime cost-effectiveness of PCV21 (given at age 50 years only, at ages 50/65 years, and risk-based at ages < 65 years plus age-based at age 65 years) compared to no vaccination and to currently recommended pneumococcal vaccines given either as currently recommended or routinely at ages 50/65 years. The analysis was conducted in hypothetical Black and non-Black cohorts aged 50 years or older, with and without considering childhood pneumococcal vaccination indirect effects. Model parameters were based on US data. Parameter uncertainty was assessed using 1-way and probabilistic sensitivity analyses. From the societal perspective, PCV21 at ages 50/65 years compared to PCV21 at age 50 years cost $7,410 per quality adjusted life year (QALY) gained in Black cohort analyses and $85,696/QALY gained in the non-Black cohort; PCV21 at ages 50/65 years had the most favorable public health outcomes. From the healthcare perspective, compared to no vaccination, PCV21 at age 50 years cost $46,213/QALY gained in the Black cohort and $86,629/QALY in non-Blacks. All other strategies were dominated in both cohorts and from both perspectives. When considering childhood pneumococcal vaccination indirect effects, costs of PCV21 at ages 50/65 years remained less than $140,000/QALY gained from the societal perspective in both populations. PCV21 is potentially cost-effective compared to currently approved pneumococcal vaccines in adults aged 50 years or older from both the societal and healthcare perspectives.
引用
- Altawalbeh SM, Wateska AR, Nowalk MP, et al. Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older. Vaccine. 2024. PMID: 38580515. doi:10.1016/j.vaccine.2024.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。